Study agents | Other agents | Disease | Dose | No Pts | Response | Clinical trial | Reference |
---|---|---|---|---|---|---|---|
Midostaurin | Etoposide Cytarabine | Relapsed Refractory | 50 mg bid | 34 | ORR 82.5% CR 56.5% | Phase I | [47] |
Midostaurin | ATRA Chemotherapy | Relapsed Refractory | 25 mg/50 mg twice daily | 10 | CR 22% CRi 11% | Phase I | [48] |
Midostaurin | Daunorubicin Cytarabine | Untreated | 50 mg twice daily | 13 | CR 92% 1-year OS 85% | Phase IB | [49] |
 |  |  |  |  | 2-year OS 62% |  |  |